Posted by Michael Wonder on 22 Mar 2024
Outlook Therapeutics receives European Union positive CHMP opinion for ONS-5010 as a treatment for wet AMD
22 March 2024 - Positive opinion serves as a basis for final decision for potential authorisation from the European Commission expected within 67 days.
Outlook Therapeutics today announced that the CHMP of the EMA has issued a positive opinion concerning the authorisation of ONS-5010/Lyteneva (bevacizumab gamma), an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration in the EU.
